KVUE Stock Overview
Operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.39 |
| 52 Week High | US$24.46 |
| 52 Week Low | US$17.67 |
| Beta | 0 |
| 1 Month Change | 0.21% |
| 3 Month Change | 10.85% |
| 1 Year Change | 19.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.05% |
Recent News & Updates
Kenvue: How To Profit Strongly, Despite Elusive Upside
Mar 25These 4 Measures Indicate That Kenvue (NYSE:KVUE) Is Using Debt Reasonably Well
Mar 25
Recent updates
Kenvue: How To Profit Strongly, Despite Elusive Upside
Mar 25These 4 Measures Indicate That Kenvue (NYSE:KVUE) Is Using Debt Reasonably Well
Mar 25Kenvue's (NYSE:KVUE) Conservative Accounting Might Explain Soft Earnings
Mar 06Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Feb 17Kenvue Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 09Kenvue Is A Mediocre Candidate
Feb 08Kenvue's (NYSE:KVUE) Dividend Will Be $0.205
Feb 06Kenvue (NYSE:KVUE) Will Pay A Dividend Of $0.205
Jan 23Kenvue Inc.'s (NYSE:KVUE) Intrinsic Value Is Potentially 70% Above Its Share Price
Jan 04Kenvue (NYSE:KVUE) Seems To Use Debt Quite Sensibly
Dec 08Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
Nov 27Kenvue: Unpacking Activist's Case And Earnings Preview
Oct 29Kenvue (NYSE:KVUE) Has Affirmed Its Dividend Of $0.205
Oct 22Investors Met With Slowing Returns on Capital At Kenvue (NYSE:KVUE)
Oct 07Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business
Oct 02Kenvue (NYSE:KVUE) Has A Pretty Healthy Balance Sheet
Sep 08
Critical Brand Investments And Operational Efficiencies Set To Spur Robust Growth And Investor Confidence
Aug 20 Strategic investments in brand marketing and launching new products like Tylenol Easy To Swallow aim at enhancing market penetration and consumer loyalty.Kenvue: Promising Steps Toward Long-Term Success
Aug 11Kenvue Is A Premier Consumer Company, But I Am Waiting For A Lower Price Before I Buy
Aug 02Is There An Opportunity With Kenvue Inc.'s (NYSE:KVUE) 36% Undervaluation?
Jul 15Kenvue: A 4% Yield Worth Going Long
Jun 12Kenvue's (NYSE:KVUE) Soft Earnings Don't Show The Whole Picture
May 21Kenvue Q1 Earnings Preview: A Potentially Troubling Trend
May 03Kenvue: Fairly Valued Spinout
Apr 17Kenvue: This Dividend Newcomer Is Worth A Look
Feb 13Kenvue: What To Expect From Its First Full-Year Report As A Standalone Company
Feb 05Kenvue: Portfolio Filled Of Market Leaders
Dec 20Kenvue: Dude, Where's My Dividend Growth?
Nov 26Kenvue: Only A Watchlist Stock For Now
Nov 19Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond
Oct 19Shareholder Returns
| KVUE | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 7.0% | 3.7% | -0.05% |
| 1Y | 19.5% | -33.3% | 5.7% |
Return vs Industry: KVUE exceeded the US Personal Products industry which returned -33.3% over the past year.
Return vs Market: KVUE exceeded the US Market which returned 5.7% over the past year.
Price Volatility
| KVUE volatility | |
|---|---|
| KVUE Average Weekly Movement | 3.9% |
| Personal Products Industry Average Movement | 9.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: KVUE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KVUE's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 22,000 | Thibaut Mongon | www.kenvue.com |
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Kenvue Inc. Fundamentals Summary
| KVUE fundamental statistics | |
|---|---|
| Market cap | US$43.61b |
| Earnings (TTM) | US$1.03b |
| Revenue (TTM) | US$15.46b |
43.6x
P/E Ratio2.9x
P/S RatioIs KVUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KVUE income statement (TTM) | |
|---|---|
| Revenue | US$15.46b |
| Cost of Revenue | US$6.47b |
| Gross Profit | US$8.99b |
| Other Expenses | US$7.96b |
| Earnings | US$1.03b |
Last Reported Earnings
Dec 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 58.14% |
| Net Profit Margin | 6.66% |
| Debt/Equity Ratio | 87.8% |
How did KVUE perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield151%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 19:24 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/29 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kenvue Inc. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |